Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III anlotinib monotherapy in advanced or metastatic soft tissue sarcoma subtypes
2017-001655-31Phase 3Completed
- Sponsor
- Advenchen Laboratories
- Start
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-arm trial of anlotinib in alveolar soft part sarcoma (ASPS), leiomyosarcoma (LMS) and synovial sarcoma (SS), sponsored by Advenchen Laboratories. Primary endpoint: Objective tumor response rate. Started Mar 2018; status: completed.
02
Drugs
anlotinib
03
Conditions
alveolar soft part sarcoma (ASPS)leiomyosarcoma (LMS)synovial sarcoma (SS)
Beyond the preview
Go deeper on 2017-001655-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001655-31.